Clinical Trials
11 trialsNCT05234684 2024-02-07
BELIEVE-01
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3 Unknown
NCT05495828 2023-10-26
Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors
Peking University People's Hospital
Unknown
NCT05978739 2023-10-25
Evaluating Different Doses of Orelabrutinib in MCL
InnoCare Pharma Inc.
Phase 2 Unknown
NCT06015464 2023-08-29
An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL
The First Affiliated Hospital with Nanjing Medical University
Unknown
NCT04014205 2023-04-18
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2 Unknown
NCT05351346 2023-03-24
Genotype-guided Treatment in DLBCL
Ruijin Hospital
Phase 3 Unknown
NCT05498259 2023-02-03
Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05322733 2022-04-19
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05076097 2021-11-11
A Study of OLR in First-line Treatment of Mantle Cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05014100 2021-08-27
Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma
Puyang Oilfield General Hospital
Phase 2 Unknown
NCT05021770 2021-08-26
Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma
Sun Yat-sen University
Phase 1/2 Unknown